Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

Besse, B. ; Springfeld, C. ; Baik, C. ; Hervieu, A. ; Solomon, B. ; Moreno, V. ; Bazhenova, L. ; Goto, K. ; Kim, Y.C. ; Lu, S. ; Sun, M. ; Trone, D. ; Thamake, S. ; Cho, B.C. ; de Langen, A. ; Popat, S. ; Wolf, J. ; Moro-Sibilot, D. ; Fang, J. ; Drilon, A.

European journal of cancer (1990), 2022-10, Vol.174, p.S75-S76 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível